Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus

E-ISSN： 2212-3938|12|4|202-209

ISSN： 1574-8847

Source： Current Clinical Pharmacology, Vol.12, Iss.4, 2018-04, pp. : 202-209

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of Type 2 diabetes mellitus based on glucagon-like peptide-1

By Holst J.J.

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 9, 1999-09 ,pp. : 1409-1415

Informa Healthcare

Access to resources Recommend Favorite

The glucagon-like peptide-1 analogue liraglutide has demonstrated promising properties for once-daily treatment of type-2 diabetes mellitus

Inpharma, Vol. 1, Iss. 1607, 2007-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

The glucagon-like peptide-1 analogue liraglutide effectively improves cardiovascular (CV) parameters in patients with type 2 diabetes mellitus

Inpharma, Vol. 1, Iss. 1560, 2006-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Glucagon-like Peptide-1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents

By Gallwitz Baptist

Drugs, Vol. 71, Iss. 13, 2011-09 ,pp. : 1675-1688

Adis International

Access to resources Recommend Favorite

Glucagon-Like Peptide-1 Synthetic Analogs: New Therapeutic Agents for Use in the Treatment of Diabetes Mellitus

Current Medicinal Chemistry, Vol. 10, Iss. 22, 2003-11 ,pp. : 2471-2483

Bentham Science Publishers

Access to resources Recommend Favorite